查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
患者肿瘤组织移植 (PDX) 模型市场 - 全球市场规模、份额、趋势分析、机会和预测报告（2019-2029）
市场调查报告书
商品编码
1391776

患者肿瘤组织移植 (PDX) 模型市场 - 全球市场规模、份额、趋势分析、机会和预测报告（2019-2029）

Patient-Derived Xenograft Model Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Tumor Type ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2029 年，患者肿瘤组织移植 (PDX) 模型的全球市场规模将成长一倍以上，达到 6.55 亿美元

由于个人化医疗需求的不断增长和癌症发病率的上升，全球患者肿瘤组织移植（PDX）模型市场正在蓬勃发展。

领先的策略咨询和市场研究公司BlueWeave Consulting在最近的研究中估计，2022年全球患者肿瘤组织移植（PDX）模型市场规模为3.1256亿美元。 BlueWeave 预测，在 2023 年至 2029 年的预测期内，患者肿瘤组织植入 (PDX) 模型的全球市场规模将以 13.1% 的复合年增长率显着增长，到 2029 年将达到 6.5491 亿美元。全球患者肿瘤组织移植（PDX）模型市场的主要成长动力包括癌症患者数量的增加、药物研发活性化以及由于公共和私人对癌症研究的持续支持而对个体化药物的需求。需求旺盛等在临床前开发过程中，遵守美国FDA 的良好生产规范 (GMP) 至关重要。小型企业创新研究和小型企业技术转移津贴等政府倡议为临床前计画提供财务支援和指导。全球对 PDX 模型的需求不断增加，预计将简化模型选择和体内功效测试。 PDX 模型涉及将患者肿瘤组织直接移植到免疫力缺乏动物体内，保留重要的细胞-肿瘤相互作用，并已被证明可用于临床前药物测试和生物标记发现。免疫力缺乏大鼠的介绍有助于大鼠 PDX 模型的建立。扩大研发活动以及政府和私营部门对癌症研究的持续支持正在推动市场成长。然而，在分析期间，高成本、技术专长、道德问题预计将抑制整体市场的成长。

该报告的详细分析提供了有关全球患者肿瘤组织植入（PDX）模型市场的成长潜力、未来趋势和统计数据的资讯。我们也研究了推动市场总规模预测的因素。该报告致力于提供全球患者肿瘤组织植入（PDX）模型市场的最新技术趋势以及产业见解，以帮助决策者做出策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球患者肿瘤组织植入（PDX）模型市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 个人化医疗需求不断成长
      • 癌症发生率增加
    • 抑制因素
      • 高成本和技术专长
      • 道德问题
    • 机会
      • 扩大研发
      • 协作与伙伴关係
    • 任务
      • 模型变异性
      • 监管障碍
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第4章全球病患肿瘤组织移植（PDX）模型市场概述

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
      • 小鼠模型
      • 大鼠模型
    • 按肿瘤类型
      • 胃肠道肿瘤模型
      • 妇科肿瘤模型
      • 呼吸道肿瘤模型
      • 泌尿系统肿瘤模型
      • 血液肿瘤模型
      • 其他的
    • 按最终用户
      • 製药和生物技术公司
      • 学术研究所
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区
      • 中美洲和南美洲
      • 中东/非洲

第5章北美病患肿瘤组织移植（PDX）模型市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按肿瘤类型
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第6章欧洲病患肿瘤组织移植（PDX）模型市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按肿瘤类型
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太病患肿瘤组织移植（PDX）模型市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按肿瘤类型
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第8章拉丁美洲患者肿瘤组织移植（PDX）模型市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按肿瘤类型
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他中美洲和南美洲

第9章中东和非洲病患肿瘤组织移植（PDX）模型市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 按肿瘤类型
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第10章竞争形势

  • 主要企业及其产品列表
  • 全球患者肿瘤组织移植 (PDX) 模型市场占有率分析 (2022)
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）

第11章COVID-19 对全球病患肿瘤组织移植（PDX）模型市场的影响

第12章公司简介（公司简介、财务矩阵、竞争形势、关键人力资源、主要竞争、联络地址、策略展望、SWOT分析）

  • JSR Corporation
  • Wuxi Apptec
  • The Jackson Laboratory
  • Charles River Laboratories International, Inc.
  • Taconic Biosciences, Inc.
  • Oncodesign Precision Medicine
  • Inotiv, Inc.
  • Pharmatest Services
  • Hera BioLabs
  • EPO Berlin-Buch GmbH
  • Xentech
  • Urosphere
  • Altogen Labs
  • Abnova Corporation
  • 其他主要企业

第13章主要战略建议

第14章调查方法

简介目录
Product Code: BWC23932

Global Patient-Derived Xenograft (PDX) Model Market Size More Than Doubles to Touch USD 655 Million by 2029.

Global patient-derived xenograft (PDX) model market is flourishing because of the rising demand for personalized medicine and growing cancer incidence.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global patient-derived xenograft (PDX) model market size at USD 312.56 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global patient-derived xenograft (PDX) model market size to grow at a significant CAGR of 13.1% reaching a value of USD 654.91 million by 2029. Major growth drivers for the global patient-derived xenograft model market include an increasing cancer case, heightened pharmaceutical R&D, and rising demand for personalized medicines with continued support from public and private sectors for cancer research. Adherence to the US FDA Good Manufacturing Practices (GMPs) is crucial in preclinical development. Governments' initiatives, like Small Business Innovative Research and Small Business Technology Transfer Grants, offer financial support and guidance for preclinical programs. Anticipated PDX model demand is rising globally, simplifying model selection and in vivo efficacy trials. The PDX model involves direct implantation of patient tumor tissue into immune-compromised animals, preserving vital cell-tumor interactions and proving valuable in preclinical drug testing and biomarker discovery. The introduction of immunodeficient rats will facilitate PDX models in rats. Expanding R&D activities and consistent government and private sector support for cancer research drive market growth. However, high cost and technical expertise and ethical concerns are anticipated to restrain the overall market growth during the period in analysis.

Global Patient-Derived Xenograft (PDX) Model Market - Overview

The global patient-derived xenograft (PDX) model market refers to the market encompassing the use of specialized laboratory mice or other animals to implant human tumor tissues. These PDX models are created by directly transplanting cancerous tissue from a patient into an immune-deficient animal, preserving the essential interactions between human cancer cells and the surrounding microenvironment. They serve as vital tools for preclinical research in oncology, allowing scientists and researchers to study the behavior of human tumors in a more clinically relevant setting. The market includes the development, utilization, and supply of PDX models to facilitate drug testing, biomarker discovery, and co-clinical investigations in the quest for more effective cancer treatments and personalized medicine.

Impact of COVID-19 on Global Patient-derived xenograft (PDX) model Market

COVID-19 pandemic adversely affected the global patient-derived xenograft (PDX) model market. With lockdowns, restrictions on laboratory operations, and supply chain interruptions, research activities were temporarily halted or delayed. Access to resources and animal models required for PDX model development became constrained. Furthermore, prioritization of COVID-19 research led to a diversion of resources and funding. However, as the pandemic highlighted the importance of personalized medicine, it also emphasized the significance of PDX models in cancer research. As restrictions eased, the market rebounded, driven by the growing need for innovative cancer treatments and therapies.

Global Patient-Derived Xenograft (PDX) Model Market - By Tumor Type

Based on tumor type, the global patient-derived xenograft (PDX) model market is divided into Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, and Hematological Tumor Models segments. The respiratory tumor model segment holds the highest share in the global patient derived xenograft model market by tumor type, due to the increased prevalence of respiratory cancers worldwide, leading to a heightened focus on developing models to study these tumors. Lung cancer, for instance, remains a leading cause of cancer-related deaths globally, necessitating a robust platform for research. PDX models for respiratory tumors enable researchers to closely mimic and study these cancers in vivo, facilitating the development of innovative therapies and treatment strategies. This growing demand for effective respiratory tumor models propels the segment's dominance in the global PDX model market.

Competitive Landscape

Major players operating in the global patient-derived xenograft (PDX) model market include: JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Patient-Derived Xenograft (PDX) Model Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Patient-Derived Xenograft (PDX) Model Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Patient-Derived Xenograft (PDX) Model Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising demand for personalized medicine
      • 3.2.1.2. Growing cancer incidence
    • 3.2.2. Restraints
      • 3.2.2.1. High cost and technical expertise
      • 3.2.2.2. Ethical concerns
    • 3.2.3. Opportunities
      • 3.2.3.1. Expansion in research and development
      • 3.2.3.2. Collaborations and partnerships
    • 3.2.4. Challenges
      • 3.2.4.1. Model variability
      • 3.2.4.2. Regulatory hurdles
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Patient-Derived Xenograft (PDX) Model Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Mice Model
      • 4.2.1.2. Rats Model
    • 4.2.2. By Tumor Type
      • 4.2.2.1. Gastrointestinal Tumor Model
      • 4.2.2.2. Gynecological Tumor Model
      • 4.2.2.3. Respiratory Tumor Model
      • 4.2.2.4. Urological Tumor Models
      • 4.2.2.5. Hematological Tumor Models
      • 4.2.2.6. Others
    • 4.2.3. By End User
      • 4.2.3.1. Pharmaceutical & Biotechnology Companies
      • 4.2.3.2. Academic & Research Institutions
      • 4.2.3.3. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Patient-Derived Xenograft (PDX) Model Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Tumor Type
    • 5.2.3. By End User
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Tumor Type
      • 5.2.4.1.3. By End User
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Tumor Type
      • 5.2.4.2.3. By End User

6. Europe Patient-Derived Xenograft (PDX) Model Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Tumor Type
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Tumor Type
      • 6.2.4.1.3. By End User
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Tumor Type
      • 6.2.4.2.3. By End User
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Tumor Type
      • 6.2.4.3.3. By End User
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Tumor Type
      • 6.2.4.4.3. By End User
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Tumor Type
      • 6.2.4.5.3. By End User
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Tumor Type
      • 6.2.4.6.3. By End User
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Tumor Type
      • 6.2.4.7.3. By End User
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Type
      • 6.2.4.8.2. By Tumor Type
      • 6.2.4.8.3. By End User
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Type
      • 6.2.4.9.2. By Tumor Type
      • 6.2.4.9.3. By End User

7. Asia-Pacific Patient-Derived Xenograft (PDX) Model Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Tumor Type
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Tumor Type
      • 7.2.4.1.3. By End User
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Tumor Type
      • 7.2.4.2.3. By End User
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Tumor Type
      • 7.2.4.3.3. By End User
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Tumor Type
      • 7.2.4.4.3. By End User
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Tumor Type
      • 7.2.4.5.3. By End User
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Tumor Type
      • 7.2.4.6.3. By End User
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Tumor Type
      • 7.2.4.7.3. By End User
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Tumor Type
      • 7.2.4.8.3. By End User
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Tumor Type
      • 7.2.4.9.3. By End User
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Tumor Type
      • 7.2.4.10.3. By End User

8. Latin America Patient-Derived Xenograft (PDX) Model Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Tumor Type
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Tumor Type
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Tumor Type
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Tumor Type
      • 8.2.4.3.3. By End User
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Tumor Type
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Tumor Type
      • 8.2.4.5.3. By End User

9. Middle East & Africa Patient-Derived Xenograft (PDX) Model Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Tumor Type
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Tumor Type
      • 9.2.4.1.3. By End User
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Tumor Type
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Tumor Type
      • 9.2.4.3.3. By End User
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Tumor Type
      • 9.2.4.4.3. By End User
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Tumor Type
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Tumor Type
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Tumor Type
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Tumor Type
      • 9.2.4.8.3. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Patient-Derived Xenograft (PDX) Model Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Patient-Derived Xenograft (PDX) Model Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. JSR Corporation
  • 12.2. Wuxi Apptec
  • 12.3. The Jackson Laboratory
  • 12.4. Charles River Laboratories International, Inc.
  • 12.5. Taconic Biosciences, Inc.
  • 12.6. Oncodesign Precision Medicine
  • 12.7. Inotiv, Inc.
  • 12.8. Pharmatest Services
  • 12.9. Hera BioLabs
  • 12.10. EPO Berlin-Buch GmbH
  • 12.11. Xentech
  • 12.12. Urosphere
  • 12.13. Altogen Labs
  • 12.14. Abnova Corporation
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations